Abstract:Cefixime is a broad-spectrum oral antibiotic used for treating a wide variety of bacterial infections. Study Objective: The objective of this study was to find out whether bioequivalence study of Cefixime 200 mg, Profim® capsule manufactured by PT Promedrahardjo Farmasi Industri in comparison with Cefixime 100 mg, Cefspan® capsule manufactured by PT Dankos Farma, For PT Kalbe Farma Tbk, under license by Astellas Pharma Inc., Osaka – Japan. Methods: The study was conducted using an open-label, randomized, single-dose, two-periods, two-treatments, crossover study under fasting conditions with 8 (eight) days washed-out period between each period. According to the random design, a single oral dose of the test drug or reference drug was administered to 30 healthy male subjects after overnight fasting. The number of subjects who finished the study was twenty-eight (28) healthy male subjects. Serial plasma samples were obtained over a 32 hours period. Plasma concentrations of the drug were determined by LC-MS/MS method. From the Cefixime concentration vs. time curves, the following pharmacokinetic parameters were obtained: AUC0-32h, AUC0-∞, and Cmax, while the statistical interval proposed was 80.00 - 125.00% for AUC0-32h and Cmax with 90% Confidence Interval (CI) with α = 5.00%. The estimation of Tmax and T1/2 in the bioequivalence study was based on a nonparametric statistical procedure on the original data using Wilcoxon Sign Test. Results: The main pharmacokinetic parameters of the test drug Profim® (BN: B051A21P-1)/ reference drug, Cefspan® (BN: KCEFB00038) ratio were as follows: AUC0-32h: 105.86 (95.41 - 117.44) with CV Intra Subjects was 22.72% and Cmax: 105.63 (95.33 - 117.03) with CV Intra Subjects was 22.43 %. Whilst TMAX of the test drug Profim® (BN: B051A21P-1)/ reference drug, Cefspan® (BN: KCEFB00038) were respectively 4.50 (3.50 – 6.00) h and 4.50 (3.00 – 6.00) h; mean T1/2 were respectively 4.18 ± 0.78 h and 4.14 ± 0.56 h; and mean Slope were respectively (-0.17) ± 0.03 h and (-0.17) ± 0.02 h. There is no adverse event that occurred during this study. Conclusion: The present study demonstrated that the evaluated test drug Profim® (BN: B051A21P-1) were bioequivalence in term of both rate and extent of absorption to the reference drug Cefspan® (BN: KCEFB00038).

The Kinetics of Cefuroxime in Ascitic and Pleural Fluid.

Cefepime Clinical Pharmacokinetics

Clinical Pharmacokinetics and Pharmacodynamics of Cefepime

Penetration of cefpodoxime proxetil in lung parenchyma and epithelial lining fluid of noninfected patients

Synthesis, Characterization, Bioavailability and Antimicrobial Studies of Cefuroxime-Based Organic Salts and Ionic Liquids

Study on the pharmacokinetics of Cefazolin and HPLC assay for the serum concentration

Pharmacokinetics of cefuroxime in patients with renal failure after a single dose intravenous

Incremental Research Approach to Describing the Pharmacokinetics of Ciprofloxacin During Extracorporeal Membrane Oxygenation.

Antibiotic pharmacokinetics in infected pleural effusions

Cefepime pharmacokinetics in adult extracorporeal membrane oxygenation patients

In vitro Activity of Cefmetazole and Flomoxef among Extended-Spectrum Beta-Lactamase producing Enterobacterales

Adequate cefazolin therapy for critically ill patients: can we predict active concentrations from given protein-binding data?

Intrapulmonary concentration of ciprofloxacin in patients of lower respiratory tract infection with ventilation support

Cefpodoxime Proxetil: A New, Broad-Spectrum, Oral Cephalosporin

Stability of cefuroxime sodium in some aqueous buffered solutions and intravenous admixtures

Adequacy of cefepime concentrations in the early phase of critical illness: A case for precision pharmacotherapy

Bioequivalence Study of Two Formulations of Cefixime

A Pharmacokinetic and Pharmacodynamic Study on Intravenous Cefazedone Sodium in Patients with Community-acquired Pneumonia.

Pharmacokinetics/Pharmacodynamics and tolerability of cefiderocol in the clinical setting

Using Monte Carlo Simulation to Determine Optimal Dosing Regimen for Cefetamet Sodium for Injection

The pharmacokinetics and pharmacodynamics of cefquinome against Streptococcus agalactiae in a murine mastitis model